ARTICLE | Clinical News
Mylan gets first FDA approval for an Advair generic
February 1, 2019 1:15 AM UTC
FDA approved Wixela Inhub salmeterol/fluticasone from Mylan N.V. (NASDAQ:MYL), the first generic version of Advair salmeterol/fluticasone from GlaxoSmithKline plc (NYSE:GSK; LSE:GSK), to treat asthma or chronic obstructive pulmonary disease (COPD).
Mylan plans to launch the product in the second half of February...